Christopher D. Bown, PhD

Dr. Christopher Bown is a partner and the leader of Gowling WLG’s Patent Group in Canada.

Based in Gowling WLG's Ottawa office, he has over 20 years of experience in strategic IP portfolio management and extensive expertise in drafting and prosecuting complex patent applications across a wide range of technologies, including life sciences, biotechnology and mining industries. He also provides litigation support for cases involving these types of technologies. 

Chris obtained his PhD from the Department of Medical Sciences at McMaster University and his B.Sc. (Hons. Genetics) from the University of Western Ontario. His postdoctoral research at the Neuroscience Research Institute in Ottawa focused on the transcriptional regulation of the genes encoding proteins involved in neurotransmission and the development of a diagnostic test to detect SNPs associated with major depressive disorder.

Chris assists entrepreneurs and SMEs, as well as multinational corporations, in the protection and management of their IP assets. In addition to having considerable experience in protecting inventions related to biologics, diagnostic methods, medical devices and pharmaceuticals, he has an in-depth knowledge of a wide variety of different disciplines, including ultra-deep mining technologies, viniculture, radio transmission technologies, cosmetic chemistry, and inventions related to aerospace and defence.